Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy - FLC.IV/X/22

arodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy0 个研究点目标入组 725 人开始时间: 2023年10月27日最近更新: 2024年7月22日

试验速览

暂无简介。

•1.diagnosed hypertrophic cardiomyopathy as defined by the European Society of Cardiology, 2. signed informed consent to participate in the study, 3. 18 years of age or more

•1. age <18 years of age, 2. permanent atrial fibrillation, 3. previous treatment with amiodarone, 4. absolute contraindications to ablation treatment or absolute contraindications to amiodarone administration, 5. left atrium size in short axis echocardiography > 5.5 cm or four-chamber view LA area> 35 cm2, 6. NYHA class IV heart failure, 7. double-determined left ventricular ejection fraction <30% despite optimal treatment; including at least 1 record on sinus rhythm, 8. pregnancy or breastfeeding, 9. participation in another clinical trial, 10. expected non-compliance during the study, 11. absolute contraindication to magnetic resonance imaging, 12. other important reason which, due to the researcher opinion, does not qualify the patient to participate in the study 13.Lack of consent to use contraception during the study and during the obligatory period to use contraception after the study 14.Decompensated thyroid dysfunction 15.•Indication for simultaneous use of drugs that prolong the QT interval ((class Ia antiarrhythmic drugs, e.g.: quinidine, procainamide, disopyramide; class III antiarrhythmic drugs, e.g. sotalol, bretylium; erythromycin, cotrimoxazole, pentamidine; some antipsychotics or antidepressants, e.g. chlorpromazine, thioridazine, fluphenazine, pimozide, haloperidol, amisulpride and sertindole; lithium preparations and tricyclic drugs, e.g. doxepin, maprotiline, amitriptyline, some antihistamines, e.g. terfenadine, astemizole, mizolastine)

发起方

arodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy